In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series E round brings $15.3mm to NanoString Technologies

Executive Summary

Translational research and molecular diagnostics company NanoString Technologies Inc. has raised $15.3mm through its Series E round. New investors Morgan Stanley Expansion Capital and AllianceBernstein Alternative Investment Management Group were joined by returning backers Clarus Ventures, Draper Fisher Jurvetson, OVP Venture Partners, GE Healthymagination Fund, BioMed Ventures, and individual investor Henri Termeer. Proceeds will fund ongoing life sciences offerings, including the nCounter expression analysis system, and will also support the international market launch of NanoString’s first molecular diagnostics product, a breast cancer assay based on the PAM50 gene expression signature. The assay recently received the CE Mark, and is still in development in the US.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies